U.S. markets closed

Affimed N.V. (AFMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.65-0.09 (-0.92%)
At close: 4:00PM EDT

10.00 +0.35 (3.63%)
After hours: 7:52PM EDT

Sign in to post a message.
  • A
    Anonymous
    I just reviewed (again) AFMD's latest presentation. It reminded me that they are funded into 2023 but, considerably more important, they have a deep pipeline AND several leading drug companies as development partners.
    Putting this all together (and not forgetting Point 72's position) I've come to the conclusion that a deal will in all likelihood be struck at the latest by late 2022.
    As to the price, while additional clinical developments will be reported in the next 12-18 months, I also believe that we'll be taken out for somewhere north of $10 Billion.......
  • t
    thomas
    With the recent news if you’re patient $25 stock within a month or so and possibly $70 per share by year end
  • A
    Anonymous
    Steve Cohen taking a position in a relatively small cap company (AFMD) tells me he expects substantially higher prices through internal generation (pipeline development/ expansion) or external factors (takeover). When he instituted a position in Immunomedics (at, as I recall, about $10/ share, it wasn't long before the takeover occurred at a huge premium. I'm not saying history will repeat here but the guy does have connections and a great touch....No reason to exit before the outcome is determined which I also believe will be relatively soon ("soon" being within a year).
  • g
    gene_genome
    Analyst Actions: BMO Capital Adjusts Affimed's Price Target to $15 From $12, Keeps Outperform Rating
  • A
    Anonymous
    AFMD hit $24 back in July 2015. My guess is that Roche, the lead dog with the inside track (or any other potential buyer of the company) will probably have to pay at least $24....and hopefully a bit more depending upon the pipeline's evolution and future prospects of their lead drug plus other candidates.

    It's usually never good to sit back and do nothing with a stock but if you own AFMD, that now becomes the best strategy as I expect a "resolution" (deal) within 12 months. Trying to trade around a position could be dangerous as the hammer may fall at any time.
  • B
    Bill
    FDA Calendar
    Phase 1 early data to be presented at AACR meeting April 13, 2021 at 1:30pm ET. Data released April 9, 2021 noted 100% response rate (2/4 partial responses and 2/4 complete responses).
    Bullish
  • a
    ageninrussia
    Arguably, most important takeaway from today’s data is that $AFMD bi-specific antibodies add high affinity targeting to NK-cells.

    Offer manufacturing benefits over CAR-NK. No cell modification and doesn't sacrifice efficacy. Validates Affimed as NK combo partner
  • H
    Hound
    More upgrades and increased price targets to follow these incredible clinical results!
  • B
    Bill
    Congratulations' to those holders and traders with this great news with more to come.
    AACR: Germany's small NK cell player Affimed makes a big splash with early lymphoma data
    https://endpts.com/aacr-germanys-small-nk-cell-player-affimed-makes-a-big-splash-with-early-lymphoma-data/
    German small-cap Affimed has long been highlighted as a potential Cinderella story, winning milestone-rich deals with Genentech and Roivant. And on Friday the biotech continued its NK cell march, presenting the first look at in-human data ahead of th
    German small-cap Affimed has long been highlighted as a potential Cinderella story, winning milestone-rich deals with Genentech and Roivant. And on Friday the biotech continued its NK cell march, presenting the first look at in-human data ahead of th
    endpts.com
    Bullish
  • F
    FfcP
    Many talking about this crashing from it high, other that they will dilute. Well, let me tell you that since I bought it @1.6$/share not only I have heard the same arguments but also every time this stock has decreased in price after reaching a peak, eventually it has touched higher heights. This is a serious company, they will eventually dilute in the future to move with their pipeline but they know better than doing it now and killing the momentum...The price target was 15$, but if this company continues presenting good results 5 to 10 years from now that 15 $ mark will look like a steal. Point is, i will hold longer than I thought initially that I would do. Good luck to all.
  • P
    Phillip
    not a bad day so far. anybody think it worth holding until earnings next week.
    Bullish
  • V
    Van Brempt
    Globe Newswire 09 april 2021 11:59AM
    Did you notice this:
    Heavily pretreated with between 4 and 14 previous
    Lines of therapy...
    Sounds incredible!
  • M
    Me
    Hope you guys who are calling the top for this stock are actually putting their money at risk and shorting this stock. If you've been following the progress of this company, you'd know that AFM13 is the weakest of their products in the clinic. Next generation of product will perform even better and that will be the milestone for increase in stock price.
  • F
    Frogman
    Solid results with room to run. Next level is 20.00 buckeroos. Congrats AFMD. Maybe the daytraders and WallStreet Bets can run this puppy up.
  • S
    Sid
    Bought 2000 for $9,8 average
  • F
    Frogman
    Agree add add add add. AACR news was quite astounding. This stock is giving you the gift of a happy 2021 celebration Wowowowwo
  • S
    Sid
    Looks like great data for remissions of blood cancer. But only phase 1 data. Mulling this over.
  • S
    Submarine
    I have to keep posting good news here.

    Affimed gets FDA green light to go ahead with AFM24+SNK-01 study in solid tumors, shares up 4%
    Bullish
  • J
    Jim
    The big question............What will happen in one week? After AACR presentations.
  • B
    Benny Padilla
    A cure for tumors and this is all the pop shareholders get?